Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
基本信息
- 批准号:9250797
- 负责人:
- 金额:$ 18.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:6 year oldAddressAffectAge of OnsetAlanineAllergicAllergic rhinitisAnimal ModelArginineAsthmaAtopic DermatitisBiochemical PathwayBiologicalBiological FactorsBiological ProcessBirthCarnitineCessation of lifeChildChildhoodChildhood AsthmaChronicChronic DiseaseClinicalComplexDataData SourcesDevelopmentDiagnosisDiagnosticDiseaseDisease PathwayEarly InterventionEndocrine System DiseasesEnrollmentEnvironmentEnvironmental ExposureEnvironmental Risk FactorEtiologyExploratory/Developmental GrantExposure toFamilyFrequenciesFunctional disorderGoalsHeterogeneityHospitalizationHypersensitivityIgEInborn Errors of MetabolismIndividualInfantInfectionInterventionLeadLifeLongitudinal StudiesLower Respiratory Tract InfectionLungLung InflammationMeasurementMeasuresMedicalMetabolicModelingMorbidity - disease rateNatureNeonatal ScreeningNewborn InfantOxidative StressPerinatal ExposurePharmaceutical PreparationsPhenotypePredispositionPreventionProspective cohortProspective cohort studyPublic HealthResearchRespiratory Signs and SymptomsRespiratory Tract InfectionsRespiratory physiologyRespiratory syncytial virusRiskRisk FactorsRoleSensitivity and SpecificitySeveritiesSupplementationSymptomsTennesseeTestingUnited StatesWheezingasthma preventionbasecohortcostdesignearly childhoodhigh riskimprovedmitochondrial dysfunctionnovelnovel strategiesoxidationpopulation basedpredictive modelingpreventprogramspublic health relevancerespiratoryrespiratory healthscreeningstressortool
项目摘要
DESCRIPTION (provided by applicant): Childhood asthma is a devastating condition that incurs long-term medical and financial burdens for affected children and their families. But identifying young children at high risk to develop asthma has proven difficult. Current predictive models are simplistic and do not recognize the underlying complexity of asthma; however, more complex models tend to lose clinical utility. Yet such models are needed: asthma is one of the most common chronic childhood diseases, affecting seven million children in the United States alone. Recent studies suggest that clustering early childhood respiratory and allergy symptoms (i.e., wheezing, respiratory infections, atopic dermatitis) into distinct phenotypes may improve the ability to predict asthma development in children. However, little is known about the biologic risks underlying these phenotypes. Metabolic and mitochondrial dysfunction, for instance, has been associated with asthma, but critical gaps remain in our understanding of how it leads to development of the disease. Newborn metabolic screening is a public health initiative aimed at screening every child born for endocrine disorders and rare inborn errors of metabolism, including many disorders indicative of metabolic and mitochondrial dysfunction. This screening represents a unique data source that can be analyzed alongside perinatal and environmental exposures to further our understanding of asthma etiology. We hypothesize that individuals with mild metabolic disturbances at birth will be more prone to further metabolic and mitochondrial dysfunction leading to the development of respiratory and allergy phenotypes later in childhood when exposed to triggers in the environment or to other stressors. Using two prospective cohort studies from Tennessee designed to identify risk factors for asthma; we will address this hypothesis through the following specific study goal and aims. Specific Study Goal: Determine if inclusion of newborn metabolic screening data improves prediction of early childhood respiratory and allergy phenotypes. Aim 1: Identify clusters of respiratory phenotypes based on early childhood respiratory and allergy symptoms. Aim 2: Identify clinical, demographic, environmental and newborn metabolic screening metabolites that are predictive of infant respiratory morbidity and asthma and allergy phenotypic groups. Aim 3: Validate predictive models and determine the sensitivity and specificity of our model. Combining clinical and environmental data with data, such as neonatal screening measurements, routinely captured by state programs is a novel approach for creating predictive models that can be incorporated into clinically available tools, account for heterogeneity in asthma phenotypes, and uncover novel disease pathways. If this approach is successful, our predictive models will improve the diagnosis of asthma in childhood and possibly lead to prevention or strategies for early intervention of a significant illness that affects millions of children worldwide.
描述(由申请人提供):儿童哮喘是一种毁灭性的疾病,会给受影响的儿童及其家庭带来长期的医疗和经济负担。但事实证明,识别患有哮喘的高危儿童是困难的。目前的预测模型过于简单,没有认识到哮喘的潜在复杂性;然而,更复杂的模型往往失去临床实用性。然而,这样的模型是必要的:哮喘是最常见的慢性儿童疾病之一,仅在美国就影响着700万儿童。最近的研究表明,聚集早期儿童呼吸道和过敏症状(即,哮喘、呼吸道感染、特应性皮炎)转化为不同的表型可能提高预测儿童哮喘发展的能力。然而,对这些表型的生物学风险知之甚少。例如,代谢和线粒体功能障碍与哮喘有关,但我们对它如何导致疾病发展的理解仍然存在重大差距。新生儿代谢筛查是一项公共卫生举措,旨在筛查每一个出生的儿童是否患有内分泌失调和罕见的先天性代谢缺陷,包括许多表明代谢和线粒体功能障碍的疾病。这种筛查代表了一种独特的数据来源,可以与围产期和环境暴露一起分析,以进一步了解哮喘病因。我们假设,出生时轻度代谢紊乱的个体更容易发生进一步的代谢和线粒体功能障碍,导致在儿童期后期暴露于环境中的触发物或其他应激源时出现呼吸和过敏表型。使用田纳西州的两项前瞻性队列研究,旨在确定哮喘的危险因素;我们将通过以下特定的研究目标和目的来解决这一假设。具体研究目标:确定是否包括新生儿代谢筛查数据改善了早期儿童呼吸和过敏表型的预测。目的1:根据儿童早期呼吸道和过敏症状识别呼吸道表型簇。目标二:确定临床、人口统计学、环境和新生儿代谢筛查代谢物,这些代谢物可预测婴儿呼吸道发病率、哮喘和过敏表型组。目的3:验证预测模型并确定我们模型的灵敏度和特异性。将临床和环境数据与国家计划常规捕获的数据(如新生儿筛查测量)相结合,是创建预测模型的一种新方法,该模型可以纳入临床可用的工具中,解释哮喘表型的异质性,并发现新的疾病途径。如果这种方法成功,我们的预测模型将改善儿童哮喘的诊断,并可能导致预防或早期干预影响全球数百万儿童的重大疾病的策略。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Initial Metabolic Profiles Are Associated with 7-Day Survival among Infants Born at 22-25 Weeks of Gestation.
- DOI:10.1016/j.jpeds.2018.03.032
- 发表时间:2018-07
- 期刊:
- 影响因子:0
- 作者:Oltman SP;Rogers EE;Baer RJ;Anderson JG;Steurer MA;Pantell MS;Partridge JC;Rand L;Ryckman KK;Jelliffe-Pawlowski LL
- 通讯作者:Jelliffe-Pawlowski LL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tina V Hartert其他文献
Tina V Hartert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tina V Hartert', 18)}}的其他基金
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
- 批准号:
10230392 - 财政年份:2020
- 资助金额:
$ 18.76万 - 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
- 批准号:
10301922 - 财政年份:2020
- 资助金额:
$ 18.76万 - 项目类别:
Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
- 批准号:
9090671 - 财政年份:2016
- 资助金额:
$ 18.76万 - 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
- 批准号:
10460524 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
- 批准号:
9975086 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
- 批准号:
10262868 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
RSV to Asthma Cooperative Clinical Ascertainment and Biospecimen Research Core
RSV 与哮喘合作临床确定和生物样本研究核心
- 批准号:
8196536 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
- 批准号:
10675721 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
RSV and asthma: Defining host and exposure variation on disease development
RSV 和哮喘:定义疾病发展的宿主和暴露变异
- 批准号:
10460527 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Research Grant














{{item.name}}会员




